Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 25;29(9):2216–2223. doi: 10.1038/s41591-023-02494-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Crown 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 1 — This schema reflects the basket trial approach taken in this Phase 1 study AROANG1001 to evaluate early proof of-concept, in which healthy participants (HPs) and patients with various dyslipidemias were enrolled. In this report, we present the key results from this study showing the safety, tolerability, and pharmacodynamic effects of single ascending doses of ARO-ANG3 in HPs and multiple doses of ARO-ANG3 in both HPs and a cohort of patients with baseline hepatic steatosis. These cohorts are shown in red boxes.